Key points are not available for this paper at this time.
(1) Background: Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance as genetic biomarkers. (2) Methods: A narrative review of all the available literature was performed. Only “landmark” publications were included. (3) Results: Overall, the number of PCa patients who harbor a BRCA2 mutation range between 1.2% and 3.2%. However, BRCA2 and BRCA1 mutations are responsible for most cases of hereditary PCa, increasing the risk by 3–8.6 times and up to 4 times, respectively. These mutations are correlated with aggressive disease and poor prognosis. Gene testing should be offered to patients with metastatic PCa, those with 2–3 first-degree relatives with PCa, or those aged < 55 and with one close relative with breast (age ≤ 50 years) or invasive ovarian cancer. (4) Conclusions: The individualized assessment of BRCA mutations is an important tool for the risk stratification of PCa patients. It is also a population screening tool which can guide our risk assessment strategies and achieve better results for our patients and their families.
Building similarity graph...
Analyzing shared references across papers
Loading...
Nikolaos Kalampokis
Vita-Salute San Raffaele University
Christos Zabaftis
Stavros Niarchos Foundation
Theodoros Spinos
University of Patras
Current Oncology
The Netherlands Cancer Institute
National and Kapodistrian University of Athens
University of Patras
Building similarity graph...
Analyzing shared references across papers
Loading...
Kalampokis et al. (Thu,) studied this question.
synapsesocial.com/papers/68e780b7b6db6435876f3804 — DOI: https://doi.org/10.3390/curroncol31030086